Results 131 to 140 of about 106,022 (294)

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Responses to GLP‐1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data

Obesity, EarlyView.
ABSTRACT Objective This study examined racial differences in weight loss and clinical response to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) therapy among adults with obesity using real‐world data. Methods We retrospectively analyzed our institution's Research Data Warehouse (RDW) containing deidentified data from electronic health records ...
Jordan H. Mallette, Joshua S. Speed, Seth T. Lirette, Daniel Moore, John S. Clemmer   +4 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Trends in Diagnosing Obesity: The CALOR Study

Obesity, EarlyView.
Data from the CALOR study suggest that in people with elevated BMI in the US and Japan, there is underdiagnosis of obesity and a high prevalence of diseases interrelated to obesity. ABSTRACT Objective This study aimed to describe characteristics of people with elevated BMI by presence versus absence of obesity diagnosis and trends over time.
Deborah B. Horn, Eva Lesén, Christen M. Gray, Magnus Bjursell, Hironori Waki   +4 more
wiley   +1 more source

Oral GLP‐1RA TERN‐601 for Adults With Obesity/Overweight: Placebo‐Controlled, Multiple‐Ascending‐Dose, Phase 1 and 2 Studies

Obesity, EarlyView.
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey, Julio Rosenstock, Harold E. Bays, Douglas Denham, Anita Kohli, Melanie Haines, Christopher Jones, Ellen Kwan, Erin Castelloe, Tonya Marmon, Emil Kuriakose, Cara Nelson   +11 more
wiley   +1 more source

Novel Compounds as Glucagon-Like Peptide‑1 Receptor Agonists for Treating Diabetes. [PDF]

ACS Med Chem Lett
Sabnis RW.
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source